Advisers to the U.S. Food and Drug Administration (FDA) voiced support on May 18 for Pfizer's maternal RSV vaccine even after several expressed concerns over premature births. Outside experts on the Vaccines and Related Biological Products Advisory Committee unanimously said data ...